Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

MarketWire Canada May 4, 2017

Arch Biopartners' Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

MarketWire Canada April 13, 2017

Arch Biopartners Closes Non-Brokered Private Placement Financing

Marketwired February 28, 2017

Arch Biopartners Announces TSXV Stock Ticker Symbol Change to "ARCH"

MarketWire Canada February 23, 2017

Arch Biopartners Announces Non-Brokered Private Placement Financing

MarketWire Canada February 21, 2017

Arch Biopartners Appoints Patrick Vink to Board of Directors

MarketWire Canada December 12, 2016

Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569

MarketWire Canada October 27, 2016

Arch Biopartners Announces Issuance of U.S. Patent for Metablok

MarketWire Canada October 11, 2016

GRANT OF OPTIONS TO DIRECTORS

Stockhouse.com September 27, 2016

Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569

MarketWire Canada August 10, 2016

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

MarketWire Canada July 18, 2016

Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel

MarketWire Canada July 5, 2016

Arch Biopartners Closes First Tranche of Private Placement

MarketWire Canada June 23, 2016

Arch Biopartners Announces Non Brokered Private Placement Financing

MarketWire Canada June 14, 2016

Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

MarketWire Canada June 1, 2016

Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

Marketwired April 26, 2016

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

Marketwired March 16, 2016

Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

Marketwired March 1, 2016

Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency

Marketwired February 3, 2016

Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award

Marketwired January 6, 2016